515 related articles for article (PubMed ID: 30705687)
1. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.
Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
Nutr Metab (Lond); 2019; 16():8. PubMed ID: 30705687
[TBL] [Abstract][Full Text] [Related]
2. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
Daneshi-Maskooni M; Keshavarz SA; Mansouri S; Qorbani M; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
Trials; 2017 Jun; 18(1):260. PubMed ID: 28592311
[TBL] [Abstract][Full Text] [Related]
3. Metabolic and clinical responses to Bunium Persicum (black caraway) supplementation in overweight and obese patients with type 2 diabetes: a double-blind, randomized placebo-controlled clinical trial.
Jafari-Maskouni S; Shahraki M; Daneshi-Maskooni M; Dashipour A; Shamsi-Goushki A; Mortazavi Z
Nutr Metab (Lond); 2020; 17():74. PubMed ID: 32863846
[TBL] [Abstract][Full Text] [Related]
4. Propolis supplementation in obese patients with non-alcoholic fatty liver disease: effects on glucose homeostasis, lipid profile, liver function, anthropometric indices and meta-inflammation.
Nikbaf-Shandiz M; Tutunchi H; Khoshbaten M; Nazari Bonab H; Ebrahimi-Mameghani M
Food Funct; 2022 Nov; 13(22):11568-11578. PubMed ID: 36263703
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.
Moradi F; Kooshki F; Nokhostin F; Khoshbaten M; Bazyar H; Pourghassem Gargari B
J Trace Elem Med Biol; 2021 Jan; 63():126659. PubMed ID: 33045675
[TBL] [Abstract][Full Text] [Related]
6. Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial.
Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
Nutr Metab (Lond); 2018; 15():63. PubMed ID: 30263038
[TBL] [Abstract][Full Text] [Related]
7. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ
Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104
[TBL] [Abstract][Full Text] [Related]
8. Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.
Ebrahimzadeh A; Mohseni S; Safargar M; Mohtashamian A; Niknam S; Bakhoda M; Afshari S; Jafari A; Ebrahimzadeh A; Fooladshekan S; Mohtashami A; Ferns GA; Babajafari S; Sohrabi Z
Complement Ther Med; 2024 Mar; 80():103025. PubMed ID: 38232906
[TBL] [Abstract][Full Text] [Related]
9. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
Namkhah Z; Naeini F; Mahdi Rezayat S; Mehdi Yaseri ; Mansouri S; Javad Hosseinzadeh-Attar M
Int J Clin Pract; 2021 Nov; 75(11):e14852. PubMed ID: 34516703
[TBL] [Abstract][Full Text] [Related]
10. The effects of zinc supplementation on the metabolic factors in patients with non-alcoholic fatty liver disease: a randomized, double-blinded, placebo-controlled clinical trial.
Rezaei SMA; Mohammadi F; Eftekhari MH; Ejtehadi F; Ghaem H; Mohammadipoor N
BMC Nutr; 2023 Nov; 9(1):138. PubMed ID: 38012749
[TBL] [Abstract][Full Text] [Related]
11. Effects of curcumin/turmeric supplementation on the liver enzymes, lipid profiles, glycemic index, and anthropometric indices in non-alcoholic fatty liver patients: An umbrella meta-analysis.
Molani-Gol R; Dehghani A; Rafraf M
Phytother Res; 2024 Feb; 38(2):539-555. PubMed ID: 37918958
[TBL] [Abstract][Full Text] [Related]
12. The effect of hydroxy citric acid supplementation with calorie-restricted diet on metabolic, atherogenic and inflammatory biomarkers in women with non-alcoholic fatty liver disease: a randomized controlled clinical trial.
Arefhosseini S; Tutunchi H; Nomi-Golzar S; Mahboob S; Pouretedal Z; Ebrahimi-Mameghani M
Food Funct; 2022 May; 13(9):5124-5134. PubMed ID: 35416190
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Yang K; Chen J; Zhang T; Yuan X; Ge A; Wang S; Xu H; Zeng L; Ge J
Front Immunol; 2022; 13():949746. PubMed ID: 36159792
[TBL] [Abstract][Full Text] [Related]
14. Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial.
Mansour A; Mohajeri-Tehrani MR; Samadi M; Qorbani M; Merat S; Adibi H; Poustchi H; Hekmatdoost A
Nutr J; 2021 Apr; 20(1):35. PubMed ID: 33838673
[TBL] [Abstract][Full Text] [Related]
15. Screening for non-alcoholic fatty liver disease among obese and overweight children: Prevalence and predictors.
Thiagarajan S; Shrinuvasan S; Arun Babu T
Indian J Gastroenterol; 2022 Feb; 41(1):63-68. PubMed ID: 35064452
[TBL] [Abstract][Full Text] [Related]
16. Theobromine supplementation in combination with a low-calorie diet improves cardiovascular risk factors in overweight and obese subjects with metabolic syndrome: a randomized controlled trial.
Sharifi-Zahabi E; Rezvani N; Hajizadeh-Sharafabad F; Hosseini-Baharanchi FS; Shidfar F; Rahimi M
Food Funct; 2023 Sep; 14(18):8431-8441. PubMed ID: 37615657
[No Abstract] [Full Text] [Related]
17. The effects of zinc supplementation on metabolic profile and oxidative stress in overweight/obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.
Fathi M; Alavinejad P; Haidari Z; Amani R
J Trace Elem Med Biol; 2020 Dec; 62():126635. PubMed ID: 32932174
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of Obex® in overweight and obese subjects: a randomised, double-blind, placebo-controlled clinical trial.
Cabrera-Rode E; Cubas-Dueñas I; Acosta JR; Hernández JC; González AIC; Calero TMG; Domínguez YA; Rodríguez JH; Rodríguez ADR; Álvarez Álvarez A; Valdés RE; Espinosa LJ; Belent OT; Benavides ZB; Estévez ES; Rodríguez YA; Del Valle Rodríguez J; Juliá SM
BMC Complement Med Ther; 2023 Feb; 23(1):58. PubMed ID: 36804035
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial.
El Amrousy D; Abdelhai D; Shawky D
Eur J Pediatr; 2022 Feb; 181(2):579-586. PubMed ID: 34459959
[TBL] [Abstract][Full Text] [Related]
20. Curcumin Offers No Additional Benefit to Lifestyle Intervention on Cardiometabolic Status in Patients with Non-Alcoholic Fatty Liver Disease.
Naseri K; Saadati S; Yari Z; Askari B; Mafi D; Hoseinian P; Asbaghi O; Hekmatdoost A; de Courten B
Nutrients; 2022 Aug; 14(15):. PubMed ID: 35956400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
